Fine Foods analysts trim earnings forecasts after Q1 print as shares slide 14%
Analysts have cut their earnings forecasts for Fine Foods & Pharmaceuticals N.T.M., the Italian contract development and manufacturing group, after a first-quarter result that came in broadly in line with expectations but failed to prevent a sharp pullback in the share price.
The Milan-listed company, which manufactures nutraceutical and pharmaceutical products on behalf of third-party brands, posted quarterly revenue of €58mn and statutory earnings per share of €0.41, both close to consensus estimates. The shares have nonetheless fallen 14 per cent over the past week to €8.06, suggesting that investors were positioning for a more constructive outlook from management on the trajectory of the rest of the year.
The four analysts covering the stock have responded by lowering their forward estimates. Full-year 2026 revenue is now forecast at €261.6mn, down from €274.4mn previously, while earnings per share have been cut more sharply, to €0.49 from €0.59. The revised projections still imply a 5.7 per cent year-on-year revenue increase and a 68 per cent rise in earnings per share — but the direction of revision, and the magnitude of the EPS downgrade, point to a meaningful softening in sell-side sentiment.
Notably, analyst price targets have barely budged. The consensus remains at €13.00, with the range of estimates between €12.00 at the bearish end and €14.50 at the bullish, implying that the downgrades to near-term earnings are not viewed as carrying material implications for the longer-term intrinsic value of the business. The narrow dispersion between the most optimistic and most pessimistic targets also suggests a degree of analyst confidence in the underlying business model — or, less charitably, that sell-side coverage of the name is heavily anchored on similar assumptions.
The set-up is less reassuring when placed against the wider European life sciences peer group. Fine Foods is forecast to grow revenue at around 7.6 per cent annually through to the end of 2026, broadly in line with its 6.4 per cent five-year average. The broader industry, by contrast, is expected to grow at roughly 9.5 per cent annually over the same period — leaving the Italian group on track to continue lagging the sector even as it delivers on its own historical growth profile.
That competitive shortfall sits at the heart of the investment debate around Fine Foods. The company occupies a defensible niche as a contract manufacturer for nutraceutical and pharmaceutical clients, a segment of the supply chain that has historically benefited from steady demand and structurally rising outsourcing penetration among branded drugmakers. But the growth potential is bounded by client mix, capacity and pricing dynamics, and the most aggressive expansion in the CDMO space has tended to be captured by larger and more diversified competitors with greater scale.
For investors, the more significant question is whether the modest earnings reset reflects a temporary moderation tied to the quarter's revenue mix and cost dynamics, or the beginning of a more structural narrowing of the gap between the company's growth profile and that of the broader industry. The unchanged price targets suggest the sell-side consensus, at least for now, leans toward the former interpretation — although the 14 per cent share price reaction implies that not all holders are willing to take that view at face value.